Compound Screening TRIZ Cases

Specific compounds inhibit alpha-synuclein nitration enzymes to prevent protein aggregation.

Analyzing gut microbiota alterations and secondary bile acid levels to detect carcinogenic risk.

Pre-fibrillar hemoglobin S oligomers enable compound identification through fluorescence resonance energy transfer.

Glycosylated SV2A polypeptides serve as specific receptors for botulinum neurotoxin E entry into neuronal cells.

Fluorescent dye-labeled probes bind to A-beta aggregates on an antibody-coated substrate, enabling accurate quantification of oligomer size and number.

A separase sensor uses fluorescent proteins to visualize enzyme activity in living cells.

A hydrophobic compound links to a fusion protein via a reactive linker to induce proteasomal degradation.

Luciferin derivatives bridge nonluciferase enzymes and luciferase detection, expanding assay versatility without requiring direct D-luciferin production.

Inducible promoter constructs enable functional olfactory receptor expression, overcoming conventional screening limitations.

Arrays of peptide kinase substrates immobilized on porous matrices determine pharmacological profiles through direct biochemical detection.

Segmented peptide sequences target resistant glioblastoma subpopulations, reducing tumor relapse caused by untreated migrating cancer cells.

A fluorescence polarization assay uses labeled Nrf2 peptides to screen small molecules that block the Keap1-Nrf2 interaction.

Covalent bridges stabilize MHC complexes to resolve off-target toxicities and improve specificity in TCR ligand screening.

p38 kinase inhibitors reduce DUX4 expression to halt Facioscapulohumeral muscular dystrophy progression.

JmjC domain proteins remove methyl groups from histone lysine residues through oxidative reactions, resolving the unknown mechanism for active demethylation.

An anti-Ang2 antibody specifically binds to Angiopoietin-2 to block receptor interaction.

Engineered Tetrahymena thermophila hosts produce high-density functional ion channels, resolving low folding yields in traditional mammalian cell systems.

Segments NOTCH pathway assessment into three distinct biomarker tests to resolve the contradiction between diagnostic complexity and prediction accuracy.

NTB peptides block N-type channels to provide analgesia without triggering opioid tolerance or addiction risks.

A second harmonic-active moiety labels target proteins to generate detectable optical signals upon binding.

LC/MS analysis measures desmosine and isodesmosine levels, replacing time-consuming pulmonary function tests with rapid biomarker quantification.

Luciferase reporter constructs monitor initial amplification, stable maintenance, and vegetative amplification phases of HPV replication.

A transwell co-culture system using primary human alveolar epithelial and endothelial cells to replicate the lung barrier.

Mutated RT and src loops in recombinant SH3 domains enhance binding affinity while reducing immunogenicity.

Recombinant Gram-negative bacteria translocate heterologous proteins into eukaryotic cells using Type III secretion systems.

Antibodies bind TL1A to block DR3 interaction, reducing T cell activation and cytokine production.

A biosensor system uses resonance energy transfer between Gβγ-interacting proteins and Gβ/Gγ subunits to detect molecular activation events.

Mammalian Membrane Two-Hybrid system uses split ubiquitin reconstitution to detect protein interactions in native cellular environments.

COTL1 antibodies enable precise diagnosis of blood diseases by detecting expression levels that conventional methods miss.

Human sLZIP binds PPARγ2 to form a corepressor complex with HDAC3.

Taselisib selectively degrades mutant p110alpha protein, overcoming treatment resistance while sparing wild-type cells.

Novel NEDD8 co-E3 binding pocket inhibitors disrupt neddylation pathways through specific molecular recognition mechanisms.

Agents alter integrin alpha4beta1 binding to control hematopoietic progenitor cell adhesion and migration.

High-throughput siRNA screening identifies gene targets to modulate F508del-CFTR protein activity and plasma membrane traffic.

Targeting GIP activity resolves insufficient dementia treatment by improving cognitive function through reduced blood GIP levels.

Novel GPR75 antagonists resolve solubility and metabolism trade-offs by blocking 20-HETE signaling to treat hypertension, inflammation, and tumor growth.

An ATR-FTIR sensor detects secondary structural changes in target biomolecules using vibrational spectroscopy, enabling label-free drug preselection.

Calculating net charge per residue and Uversky hydropathy scores identifies effective antigen-binding proteins to address inadequate immune therapy approaches.

Antibodies targeting the fibrinogen gamma377-395 epitope inhibit Mac-1 binding, reducing neuroinflammation while preserving blood clotting function.

Targeting non-ACE2 receptors like CNTN1 explains multi-organ tropism and improves infection outcomes.

Engineered antibodies inhibit MT-SP1 protease activity through reversed scissile bond orientation, resolving specificity and off-target effect trade-offs.

Topical quinine activates innate immunity to reduce viral loads and RNA expression in the upper respiratory tract.

Biomarker measurement enables targeted cardiovascular therapy to prevent progression from mild cognitive disorder to Alzheimer's disease.

NMR spectroscopy identifies incipient disordered structures in transcription factors, enabling active agent screening that blocks protein aggregation.

A method isolates tetrameric alpha-synuclein using NatB acetylase expression and ammonium sulfate precipitation.